These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8278330)

  • 1. [Efficacy of atovaquone in resistant toxoplasmosis in AIDS].
    Lafeuillade A; Pellegrino P; Poggi C; Profizi N; Quilichini R; Chouette I; Navarreté MS
    Presse Med; 1993 Oct; 22(33):1708. PubMed ID: 8278330
    [No Abstract]   [Full Text] [Related]  

  • 2. Failure of atovaquone in the treatment of cerebral toxoplasmosis.
    Durand JM; Cretel E; Bagneres D; Guillemot E; Kaplanski G; Soubeyrand J
    AIDS; 1995 Jul; 9(7):812-3. PubMed ID: 7546430
    [No Abstract]   [Full Text] [Related]  

  • 3. Cerebral toxoplasmosis in childhood and adult HIV infection treated with 1-4 hydroxynaphthoquinone and rapid desensitization with pyrimethamine.
    Bouboulis DA; Rubinstein A; Shliozberg J; Madden J; Frieri M
    Ann Allergy Asthma Immunol; 1995 Jun; 74(6):491-4. PubMed ID: 7788516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
    Katlama C; Mouthon B; Gourdon D; Lapierre D; Rousseau F
    AIDS; 1996 Sep; 10(10):1107-12. PubMed ID: 8874627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subacute onset of paralysis in a person with AIDS.
    Arshad S; Skiest D; Granowitz EV
    AIDS Read; 2009 Jan; 19(1):32-5. PubMed ID: 19209454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cerebral toxoplasmosis in AIDS: efficacy and good tolerance of cotrimoxazole].
    Smadja D; Lin L; Cidolit E; Neisson-Vernant C; Cabre P; Vernant JC
    Presse Med; 1994 May; 23(19):907. PubMed ID: 7937621
    [No Abstract]   [Full Text] [Related]  

  • 7. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.
    Torres RA; Weinberg W; Stansell J; Leoung G; Kovacs J; Rogers M; Scott J
    Clin Infect Dis; 1997 Mar; 24(3):422-9. PubMed ID: 9114194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone].
    Guelar A; Miró JM; Mallolas J; Zamora L; Cardenal C; Gatell JM; Soriano E
    Enferm Infecc Microbiol Clin; 1994 Mar; 12(3):137-40. PubMed ID: 8011719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atovaquone: a review.
    Haile LG; Flaherty JF
    Ann Pharmacother; 1993 Dec; 27(12):1488-94. PubMed ID: 8305784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an AIDS patient].
    Schimkat M; Althaus C; Armbrecht C; Jablonowski H; Sundmacher R
    Klin Monbl Augenheilkd; 1995 Mar; 206(3):173-7. PubMed ID: 7616727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for use of atovaquone oral suspension in adult inpatients and outpatients.
    Goodwin SD; Fish DN
    Am J Health Syst Pharm; 1995 Nov; 52(21):2460-2. PubMed ID: 8564614
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program.
    Kovacs JA
    Lancet; 1992 Sep; 340(8820):637-8. PubMed ID: 1355212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment and primary and secondary prevention of cerebral toxoplasmosis in patients with HIV infection].
    Podzamczer D
    Enferm Infecc Microbiol Clin; 1994 Mar; 12(3):158-63. PubMed ID: 8011724
    [No Abstract]   [Full Text] [Related]  

  • 14. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
    Spencer CM; Goa KL
    Drugs; 1995 Jul; 50(1):176-96. PubMed ID: 7588086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Azithromycin: new orientations].
    Coulaud JP
    Pathol Biol (Paris); 1995 Jun; 43(6):547-50. PubMed ID: 8539080
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
    Chirgwin K; Hafner R; Leport C; Remington J; Andersen J; Bosler EM; Roque C; Rajicic N; McAuliffe V; Morlat P; Jayaweera DT; Vilde JL; Luft BJ
    Clin Infect Dis; 2002 May; 34(9):1243-50. PubMed ID: 11941551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome.
    Lopez JS; de Smet MD; Masur H; Mueller BU; Pizzo PA; Nussenblatt RB
    Am J Ophthalmol; 1992 Mar; 113(3):331-3. PubMed ID: 1543229
    [No Abstract]   [Full Text] [Related]  

  • 18. Cerebral toxoplasmosis in an AIDS patient.
    Saito T; Takeuchi S; Taguchi H; Miyoshi I
    Intern Med; 2003 Jan; 42(1):131. PubMed ID: 12583637
    [No Abstract]   [Full Text] [Related]  

  • 19. [Disseminated cerebral haemorrhages in a patient with HIV infection].
    Diz S; Barbolla I; Egea M; de Luna G
    Enferm Infecc Microbiol Clin; 2011 Nov; 29(9):704-5. PubMed ID: 21803458
    [No Abstract]   [Full Text] [Related]  

  • 20. Responsiveness to a dopamine agent in Holmes tremor--case report.
    Strecker K; Schneider JP; Sabri O; Wegner F; Then Bergh F; Schwarz J; Hesse S
    Eur J Neurol; 2007 Apr; 14(4):e9-e10. PubMed ID: 17388980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.